NovaBridge Biosciences announced that new data from the expanded Phase 1 dosing study of ragistomig, a 4-1BB x PD-L1 bispecific antibody, will be presented in a poster session at the European Society for Medical Oncology - Immuno-Oncology Congress 2025 (ESMO-IO 2025) on December 10, 2025. The study focused on a new Q6W extended dosing interval, reporting strong anti-tumor efficacy in PD-L1-non-responders and an improved safety profile, including better hepatic tolerability. Interim results also include immunological data on CD8+ cell proliferation and memory T-cell activation. Ragistomig is being developed for patients who are relapsed or refractory to checkpoint inhibitors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-307454), on December 04, 2025, and is solely responsible for the information contained therein.